Biocon, an Indian biopharmaceutical business, announced the launch of its first US production facility. Based in Cranbury, New Jersey, and run by Biocon’s wholly-owned subsidiary Biocon Generics, the US FDA-approved plant can produce up to 2 billion tablets of oral solid dosage drugs annually.

In 2023, the business purchased the plant from Eywa Pharma and spent more than $30 million on improvements to build the cutting-edge facility.

“By strengthening its supply chain and diversifying its manufacturing base, this investment helps Biocon expand its global footprint more quickly,” the business stated.

Additionally, it is a strategic move for the company’s US business, allowing for improved supply reliability and quicker access to necessary therapies. A couple of the site’s items have already been commercialized, but there are still a number more in the works.

The opening of Biocon’s first US FDA-approved formulations plant in New Jersey ushers in a new era in our international growth. It is more than just a significant accomplishment; it is a confirmation of our mission to assist patients wherever they may be,” stated Kiran Mazumdar-Shaw, Chairperson of the Biocon Group.

Governor Phil Murphy of New Jersey and several business leaders attended the plant’s inauguration on Wednesday.Additionally, it is a strategic move for the company’s US business, allowing for improved supply reliability and quicker access to necessary therapies. A couple of the site’s items have already been commercialized, but there are still a number more in the works.

The opening of Biocon’s first US FDA-approved formulations plant in New Jersey ushers in a new era in our international growth. It is more than just a significant accomplishment; it is a confirmation of our mission to assist patients wherever they may be,” stated Kiran Mazumdar-Shaw, Chairperson of the Biocon Group.

Governor Phil Murphy of New Jersey and several business leaders attended the plant’s inauguration on Wednesday.

“We are becoming closer to patients, healthcare providers, and partners in this significant market thanks to this strategic investment. Managing Director and CEO of Biocon Siddharth Mittal stated, “The proximity enables us to more efficiently deliver our vertically integrated, high-quality medicines to patients across the US and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”

In the meantime, Biocon’s stock has risen 7% in the last month, reducing its year-to-date losses to 1%.

Due to deterioration in the generics category, the company’s Q1FY26 revenue and EBITDA underperformed consensus projections by 2% and 11%, respectively.

Sales of biosimilars were up 1% QoQ, while generics and CRDMOs had increases of 6% and 11% YoY, respectively.